David Moskowitz has been appointed to the newly created role as head of capital markets strategy and investor relations at Verona Pharma Plc. He joins as the company advances a new drug for chronic obstructive pulmonary disease in the clinic. Previously, he provided consulting services to biopharma and diagnostic companies and before that, was head of investor relations at the molecular diagnostic companies Trovagene Inc and Biocept Inc. Mr Moskowitz holds a degree in pharmacy from Rutgers University and an MBA in finance and pharmaceutical industry studies from Fairleigh Dickinson University, both in the US.
Verona announced the appointment on 7 January 2020
Copyright 2020 Evernow Publishing Ltd
